Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method

Michael Haas, Volker Heinemann, Michael Ståhl et al.|European Journal of Cancer|2021

Cited by 34